REPLIDYNE, INC. (a Delaware corporation) l Shares of Common Stock PURCHASE AGREEMENTPurchase Agreement • June 26th, 2006 • Replidyne Inc • Pharmaceutical preparations • New York
MERRILL LYNCH & CO. Merrill Lynch, Pierce, Fenner & Smith Incorporated, Morgan Stanley & Co. Incorporated, as Representative(s) of the several Underwriters to be named in the within-mentioned Purchase Agreement
SECOND AMENDMENT TO LICENSE AGREEMENTLicense Agreement • June 26th, 2006 • Replidyne Inc • Pharmaceutical preparations
This Second Amendment (the “Amendment”) is entered into as of February 10, 2006 (the “Second Amendment Date”) to modify the terms of the License Agreement (the “License Agreement”) dated as of March 15, 2004 (as first amended April 5, 2005), by and between DAIICHI ASUBIO PHARMA CO., LTD., a corporation organized and existing under the laws of Japan and having its registered office at 9-11, Akasaka 2-chome, Minato-ku, Tokyo 107-8541, Japan (hereinafter referred to as “DAP”) and REPLIDYNE, INC., a corporation organized and existing under the laws of the State of Delaware, having its principal business office at 1450 Infinite Drive, Louisville, Colorado 80027, U.S.A. (hereinafter referred to as “REPLIDYNE”). DAP and REPLIDYNE are sometimes referred to collectively herein as the “Parties” or individually as a “Party.”
SUPPLY AGREEMENT AMONG REPLIDYNE, INC. DAIICHI SUNTORY PHARMA CO., LTD. AND NIPPON SODA CO., LTD. DATED: DECEMBER 20TH, 2004Supply Agreement • June 26th, 2006 • Replidyne Inc • Pharmaceutical preparations • New York
[ *** ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Exchange Act of 1933, as amended.
LICENSE AGREEMENTLicense Agreement • June 26th, 2006 • Replidyne Inc • Pharmaceutical preparations • New York
This License Agreement (hereinafter referred to as the “Agreement”) made and entered into as of March 15, 2004 (hereinafter referred to as the “Effective Date”) by and between DAIICHI SUNTORY PHARMA CO., LTD., a corporation organized and existing under the laws of Japan and having its registered office at 7-2, Kojimachi 5-chome, Chiyoda-ku, Tokyo 102-8530, Japan (hereinafter referred to as “DSP”) and REPLIDYNE, INC., a corporation organized and existing under the laws of the State of Delaware, having its principal business office at 1450 Infinite Drive, Louisville, Colorado 80027, U.S.A. (hereinafter referred to as “REPLIDYNE”). DSP and REPLIDYNE are sometimes referred to collectively herein as the “Parties” or individually as a “Party”.
AMENDMENT TO LICENSE AGREEMENTLicense Agreement • June 26th, 2006 • Replidyne Inc • Pharmaceutical preparations
This Amendment (the “Amendment”) is entered into as of April 5, 2005 (the “Effective Date”) to modify the terms of the License Agreement (the “License Agreement”) dated as of March 15, 2004 by and between DAIICHI SUNTORY PHARMA CO., LTD., a corporation organized and existing under the laws of Japan and having its registered office at 7-2, Kojimachi 5-chome, Chiyoda-ku, Tokyo 102-8530, Japan (hereinafter referred to as “DSP”) and REPLIDYNE, INC., a corporation organized and existing under the laws of the State of Delaware, having its principal business office at 1450 Infinite Drive, Louisville, Colorado 80027, U.S.A. (hereinafter referred to as “REPLIDYNE”). DSP and REPLIDYNE are sometimes referred to collectively herein as the “Parties” or individually as a “Party.”
COLLABORATION AND COMMERCIALIZATION AGREEMENTCollaboration and Commercialization Agreement • June 26th, 2006 • Replidyne Inc • Pharmaceutical preparations • New York
